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Abstract
Background: The gene encoding integrator complex subunit 6 (INTS6), previously known as
deleted in cancer cells 1 (DICE1, OMIM 604331) was found to be frequently affected by allelic
deletion and promoter hypermethylation in prostate cancer specimens and cell lines. A missense
mutation has been detected in prostate cancer cell line LNCaP. Together, these results suggest
INTS6/DICE1 as a putative tumor suppressor gene in prostate cancer. In this study, we examined
the growth inhibitory effects of INTS6/DICE1 on prostate cancer cells.
Results: Markedly decreased INTS6/DICE1 mRNA levels were detected in prostate cancer cell
lines LNCaP, DU145 and PC3 as well as CPTX1532 as compared to a cell line derived from normal
prostate tissue, NPTX1532. Exogenous re-expression of INTS6/DICE1  cDNA in androgen-
independent PC3 and DU145 cell lines substantially suppressed their ability to form colonies in vitro.
This growth inhibition was not due to immediate induction of apoptosis. Rather, prostate cancer
cells arrested in G1 phase of the cell cycle. Expression profiling of members of the Wnt signaling
pathway revealed up-regulation of several genes including disheveled inhibitor CXXC finger 4
(CXXC4), frizzled homologue 7 (FZD7), transcription factor 7-like 1 (TCF7L1), and down-regulation
of cyclin D1.
Conclusion: These results show for the first time a link between INTS6/DICE1 function, cell cycle
regulation and cell-cell communication involving members of the Wnt signaling pathway.
Background
Prostate cancer is the most common malignancy and the
second leading cause of cancer-related death in men from
western countries. The American Cancer Society (ACS)
estimated for 2009, 192,280 new cases of prostate cancer
in the United States with approximately 27,360 cases end-
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ing in death (ACS, Cancer statistics, 2009). Although
these numbers reflect the recent progress in prostate can-
cer therapy, they also reveal the demand for more effective
therapeutic strategies.
Progression of prostate cancer to androgen-independence
has been associated with multiple molecular mechanisms
such as androgen receptor (AR) gene amplification, AR
gene mutations resulting in AR hypersensitivity or change
of AR specificity, involvement of coregulators, ligand
independent activation of the AR, and involvement of
tumor stem cells [1]. More recently, other androgen-inde-
pendent mechanisms involving dysregulation of several
cell-survival signaling pathways in androgen-independent
prostate cancer have also been established. Deleted In Can-
cer 1 (INTS6/DICE1) gene (OMIM 604331) was identified
to colocalize with the microsatellite marker D13S284 in
13q14.3, a region frequently affected by allelic deletion in
many solid tumors including prostate cancer [2-5].
INTS6/DICE1 missense mutations have been previously
detected in lung and prostate cancer cell lines NCI-H2126
and LNCaP respectively, and reduced INTS6/DICE1
expression appears to be associated with CpG promoter
hypermethylation in lung and prostate cancer cells [3,5-
7]. DICE1 is a 100 kD widely expressed and highly con-
served nuclear protein with predicted protein motifs rem-
iniscent of classical DEAD box helicases suggesting its
involvement in important nuclear functions such as DNA
repair, transcription or RNA splicing [2,3,8]. In agreement
with its nuclear localization, human DICE1 was detected
to be subunit 6 of the integrator complex (INTS6)
involved in small nuclear RNA processing [9]. This inte-
grator complex is competent for transcription and may be
recruited to the promoter of RNA polymerase II-depend-
ent genes. Recently, INTS6/DICE1 has been identified as
one of the target genes of CCAAT enhancer binding pro-
tein delta (C/EBPδ) which is highly expressed in growth
arrested, contact inhibited mammary epithelial cells [10].
INTS6/DICE1 is also subject to regulation by the tumor
suppressor CDC73 that is mutually inactivated in heredi-
tary and sporadic parathyroid tumors [11]. In mouse, the
INTS6/DICE1 homologue interfered with the response to
insulin-like growth factor 1 (IGF-1), and mouse and
human DICE1 cDNA suppressed anchorage-independent
growth of transformed mouse cells [12,13]. These results
suggest that INTS6/DICE1 is a tumor suppressor gene and
emphasize the need to better characterize its function.
Results
INTS6/DICE1 mRNA expression is down-regulated in 
prostate cancer cells
In order to reinforce DICE1 tumor suppressor function in
prostate cancer, we analyzed its expression in different
human androgen-dependent/-sensitive (LNCaP), andro-
gen-independent/-insensitive (DU145, PC3, PC3-ml);
and prostate cell lines isolated from prostatic primary
tumor (paired normal/tumor 1532NPTX/1532CPTX cell
lines) [14]. Northern blot showed that DICE-1 mRNA in
all the prostate tumor cell lines tested is strongly down-
regulated or undetectable compared to normal immortal-
ized prostate 1532NPTX cells and BALB/c3T3 mouse cells
transfected with the full length DICE1 cDNA (Figure 1).
Exogenous expression of DICE1 inhibits the clonogenic 
formation capacity of androgen-independent cell lines 
through an apoptosis-independent pathway
DICE1 function in prostate cancer was studied by exoge-
nously re-expressing DICE1 cDNA in the prostate tumor
cell lines PC3 and DU145. This experiment was per-
formed by transfecting the cancer cells with the pDICE1-
EGFP fusion construct or pEGFP control expression plas-
mid (Figure 2a, left). Synthesis of a DICE1-EGFP fusion
protein in PC3 (Figure 2a, right) and DU145 (data not
shown) transfected cells was shown by a band around 150
Northern blot of prostate cancer cell lines Figure 1
Northern blot of prostate cancer cell lines. LNCaP, 
DU145, PC3, PC3-ml and CPTX1532 and NPTX1532 (cells 
derived from cancer and normal prostate tissue) were ana-
lyzed using a full length DICE1 cDNA as a hybridization 
probe. BALB/c 3T3 cells transduced by full length DICE1 
cDNA were used as a positive control. The position of 
DICE1 mRNA is indicated by an arrow on the right side and 
the positions of the 18S and 28S RNA are indicated by the 
hash marks on the left side. In the lower panel the same blot 
was subsequently probed for beta actin as a control for the 
relative amount of RNA in each sample. Note that two dis-
tinct batches of mRNA were collected from prostatic cell 
lines and gave similar expression profile for DICE1 mRNA.
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kD by Western blot analysis. This size is slightly larger
than the calculated size (expected ~125 kD). Similarly, a
slightly larger than expected size band was previously
found for human endogenous DICE1 protein functioning
as integrator subunit 6 of the integrator multiprotein com-
plex [9].
Transfected cells were then tested for their ability to form
colonies in vitro in G418 supplemented selective medium.
Interestingly, we show that the re-expression of DICE1
inhibits colony formation of PC3 and DU145 cells by
50% and 90% respectively when compared to the control
pEGFP-transfected cells (Figure 2b). With the androgen-
dependent cell line LNCaP, previously shown to harbor
missense mutation D546G in the DICE1  gene [6], we
obtained inconsistent results concerning the growth-
inhibitory responses to DICE1-EGFP (data not shown).
To determine if DICE1  suppresses prostate cancer cell
growth by inducing apoptosis, we analyzed its capacity to
stimulate genomic DNA fragmentation in PC3 cells. PC3
cells were transiently transfected with pDICE1-EGFP or
pEGFP plasmid. Subsequently, genomic DNA was
extracted after 24 and 48 hours, quantified and loaded on
Inhibition of colony formation of PC3 and DU145 prostate cancer cells by pDICE1-EGFP fusion construct Figure 2
Inhibition of colony formation of PC3 and DU145 prostate cancer cells by pDICE1-EGFP fusion construct. PC3 
and DU145 cells were transiently transfected with the pEGFP or pDICE1-EGFP fusion constructs. A. Equivalent transfection 
efficiencies (30-40%) at 48 hours post-transfection were verified by reporting EGFP in situ fluorescence on the total number of 
cells (regular light) using an inverted microscope (left). Expression of constructs was analyzed in PC3 cells by Western blotting 
of EGFP and DICE1-EGFP fusion protein using an anti-GFP monoclonal antibody (right). Sizes in kilodalton (kD) are indicated 
on the left. B. After transfection, prostate cancer cells were selected over 2-3 weeks in the presence of G418 antibiotic and 
stained with 0.5% crystal violet in methanol (left). Quantitative analysis of inhibition of the colony formation in PC3 and DU145 
cells transfected with pEGFP and pDICE1-EGFP plasmid (right).
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an agarose gel. We could not detect any DNA fragmenta-
tion in PC3 transfected cells as compared to the apoptotic
positive control cells (data not shown). These results were
validated by loading higher amounts of genomic DNA
(up to 10 μg, data not shown). In our understanding, the
absence of an apoptotic signal could not be explained by
a lack of sensitivity of the present assay. Indeed, we esti-
mated approximately 30% transfection efficiency in this
experiment, which is an adequate ratio to visualize DNA
fragmentation. Additionally, we tested the capacity of
DICE1 to induce necrosis in androgen-independent cells.
As expected, this analysis performed by propidium iodide
(PI) uptake assay on prostate cancer cells did not show
any significant effect of DICE1 expression on the percent-
age of PI-positive cells (data not shown). In conclusion,
our results suggest that DICE1 is inhibiting prostate cancer
cell growth through an apoptosis- and necrosis-independ-
ent pathway.
DICE1 expression induces G1 arrest in androgen-
independent cell lines
To further understand the mechanisms involved in DICE1
growth inhibitory function, we examined the capacity of
DICE1  to modify the cell cycle distribution of normal
prostate cells RWPE-1 and prostate cancer cells LNCaP,
PC3 and DU145. Similar to results obtained with normal
RWPE-1 cells, re-expression of DICE1 in PC3 or DU145
cells induced a 30-50% cell reduction in the sub-G0 phase
(15.1 +/- 0.52 for pEGFP-PC3 versus 10.4 +/- 0.54 for
pDICE1-EGFP-PC3 and 28.4 +/- 2.21 for pEGFP-DU145
versus 14.9 -/+ 1.18 for pDICE1-EGFP-DU145), validat-
ing our hypothesis of an apoptosis-independent mecha-
nism (Figure 3a-b). Likewise, the percentage of PC3 and
DU145 cells in G0/G1 was increased about 20-30% fol-
lowing DICE1 re-expression suggesting a block in the G1-
phase of the cell cycle (Figure 3a; 47.5 +/- 0.23 for pEGFP-
PC3 versus 55.3 +/- 2.26 for pDICE1-EGFP-PC3 and 36.4
Cell cycle distribution in response to INTS6/DICE1 re-expression Figure 3
Cell cycle distribution in response to INTS6/DICE1 re-expression. A. Normal prostate (RWPE-1) and cancer prostate 
(LNCaP, PC3 and DU145) cells were transfected with pEGFP or pDICE1-EGFP expression plasmid, stained with propidium 
iodide and the DNA content was analyzed by flow cytometry. B. Quantification of flow cytometry analysis of DNA content. 
Results are represented as the average values +/- SD calculated from three separate experiments. *: P < 0.05. Note the 
increase in the G1 cell population in PC3 and DU145 cells expressing pDICE1-EGFP compared to pEGFP cancer cells.
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+/- 2.24 for pEGFP-DU145 versus 47.6 +/- 1.0 for
pDICE1-EGFP-DU145). DU145 cells re-expressing DICE1
showed an additional 20% increase in cell number in G2/
M phase emphasizing that DICE-1 could regulate the cell
cycle at different levels. In agreement with the results
obtained in the colony formation assay, the re-expression
of DICE1 in LNCaP cell line did not present any signifi-
cant effect on their cell cycle distribution.
Changes in the Wnt signaling pathway in response to 
DICE1
As previously described, inhibition of the Wnt pathway in
PC3 cells resulted in decreased colony formation in soft
agar and in vivo tumor growth [15]. Therefore, we ana-
lyzed the expression of genes related to this pathway by
PCR array. PC3 cells containing the exogenous pDICE1-
EGFP fusion construct showed differences in the expres-
sion of several genes when compared with pEGFP-trans-
fected PC3 cells indicating regulation of Wnt signaling in
response to exogenous DICE1  expression (Table 1). In
particular, genes like CXXC finger 4 (CXXC4), frizzled
homolog 7 (FZD7) and transcription factor 7-like 1
(TCF7L1) showed an up-regulation of more than 3- to 7-
fold, whereas cyclin D1 and transcription factor 7 (TCF7)
were clearly down-regulated (3.8 and 3.6 fold, respec-
tively; Table 1). To confirm the PCR array results, we
repeated the expression analysis by quantitative real-time
PCR for selected genes CXXC4, TCF7L1 and CCND1 in
DICE1- and control-transfected PC3 and DU145 cells. The
data showed a clear 3.5 fold up-regulation of TCF7L1 in
PC3 and DU145 cells in response to DICE1, whereas
CCND1 was down-regulated (1.7 and 5.3 fold, respec-
tively). In the case of CXXC4, DICE1-transfected PC3 cells
showed a more than 30-fold up-regulation, whereas a 7-
fold down-regulation was observed in DU145 cells (Fig-
ure 4).
Real-time PCR of INTS6/DICE1 responsive genes Figure 4
Real-time PCR of INTS6/DICE1 responsive genes. A. Up-regulation of INTS6/DICE1 expression in PC3 and DU145 cells 
48 hours post-transfection with DICE1-EGFP fusion construct (DICE1) or EGFP vector (EGFP) as control. B. Selected INTS6/
DICE1 responsive genes of the Wnt signaling pathway, CXX finger 4 (CXXC4), cyclin D1 (CCND1) and transcription factor 7-
like 1 (TCFL1) monitored 48 hours after exogenous DICE1 expression in PC3 and DU145 cells. The fold change in gene expres-
sion was determined by the comparative C(T) method using G3PDH as reference.
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Discussion
Previous studies provided functional evidence that the
INTS6/DICE1 gene acts as a tumor suppressor gene [13].
Regarding prostatic tumorigenesis, INTS6/DICE1 expres-
sion is down-regulated in multiple prostate cancer cell
lines as compared to normal prostate cells, and its exoge-
nous re-expression in cancer cells leads to inhibition of
their capacity to form colonies in vitro. However, few
results exist on the molecular mechanisms involved in
INTS6/DICE1 growth-inhibitory function. In a mouse tis-
sue culture model with IGF-IR transformed Balb/c 3T3
cells, it has been shown that mouse and human DICE1
cDNA inhibit anchorage-independent growth [12,13].
These results suggested a link between the IGF-IR signal-
ing system and DICE1 function. Anchorage-independent
growth, suppression of apoptosis, cell migration, invasion
and metastasis are particularly abolished in mouse tumor
cells by mutational changes of tyrosine residues 1250 and
1251 positioned outside the kinase domain of IGF-IR [16-
18]. In human prostate cancer cells, blockade of IGF-IR
expression by antisense cRNA inhibits proliferation and
invasion and leads to an enhanced rate of spontaneous
apoptosis [19]. However, apoptotic death was not
observed when investigating the capacity of exogenous
INTS6/DICE1  to induce the fragmentation of genomic
DNA in prostate cancer cells. This suggested that DICE1
protein inhibits clonogenic cancer cell growth by bypass-
ing an immediate apoptotic response. In agreement with
this hypothesis, we were able to show that DICE1  re-
expression in androgen-independent prostate cancer cells
induced cell arrest in the G1 phase of the cell cycle identi-
fying a molecular mechanism by which DICE1 could limit
prostate cancer cell growth.
INTS6/DICE1 has been proposed to be a distant member
of the DEAD box containing helicase superfamily II [3,8].
In this context, DICE1 protein has been recently identified
as subunit 6 (INTS6) of the multi-protein Integrator com-
plex involved in RNAPII-dependent transcription and
processing of small nuclear RNA [9]. It now appears that
modification in the expression level of INTS6/DICE1
could alter multi-protein complexes and consequently the
gene expression profile in these cells. In prostate cancer
with down-regulated INTS6/DICE1 expression, its exoge-
nous expression may result in reassembly of DICE1 con-
taining multi-protein complexes thus affecting distinct
signaling pathways. Both IGF-1 receptor and Wnt signal-
ing are fundamental pathways in tissue and organ devel-
opment. Cross-talk between IGF-IR and Wnt signaling has
been previously recognized during epithelium to mesen-
chymal transition as well as in Wnt-1/PTEN double trans-
genic mice [20,21]. A possible involvement of INTS6/
DICE1 in growth arrest induction by serum and growth
factor withdrawal and contact inhibition may also be
inferred from the observation that INTS6/DICE1 is one of
the primary target genes of C/EAPδ [10]. In fact, aberrantly
activated Wnt signaling has also been implicated in pros-
tate tumorigenesis and inhibition of the Wnt pathway in
PC3 cells resulted in decreased colony formation in soft
agar and in vivo tumor growth [22].
Table 1: Expression profiling of Wnt signaling pathway in INTS6/DICE1 transfected PC3 cells
Gene Symbol Description GenBank FC
Upregulated genesa
AXIN1 Axin 1 NM_003502 2.14
CTBP2 C-terminal binding protein 2 NM_022802 2.14
CXXC4 CXXC finger 4 NM_025212 7.5
FZD7 Frizzled homolog 7 (Drosophila) NM_003507 4.0
JUN Jun Oncogen NM_002228 2.8
MYC V-myc myelocytomatosis viral oncogen homolog (avian) NM_002467 4.0
SLC9A3R1 Solute carrier family 9 (sodium/hydrogen exchanger) NM_004252 2.64
T T, brachyury homolog (mouse) NM_003181 2.3
TCF7L1 Transcription factor 7-like 1 (T-cell specific, HMG-box) NM_031283 3.24
TLE Transcucin-like enhancer of split (E(sp1)homolog, Drosophila NM_005077 2.14
WISP1 WNT1 inducible signalling pathway protein NM_003882 3.24
WNT3 Wingless-type MMTV integration site family, member 3 NM_030753 2.3
WNT5B Wingless-type MMTV integration site family, member 5B NM_032642 3.5
Downregulated genesb
APC Adenomatosis polyposis coli NM_000038 -2.5
BTRC Beta-transducin repeat containing NM_033637 -2.7
CCND1 Cyclin D1 NM_053056 -3.8
FBXW2 F-box and WD repeat domain containing 2 NM_012164 -3.3
FZD6 Frizzled homolog 6 (Drosophila) NM_003506 -2.5
SENP2 SUMO1/sentrin/SMT3 specific peptidase 2 NM_021627 -2.3
TCF7 Transcription factor 7 (T-cell specific, HMG-box) NM_003202 -3.6
a: FC, fold change >2, b: FC, fold change <0,5Cancer Cell International 2009, 9:28 http://www.cancerci.com/content/9/1/28
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Conclusion
The results obtained in this study link DICE1 function to
fundamental pathways involved in cell cycle regulation
and cell-cell communication. Understanding DICE1
modes of action as it relates specifically to its regulatory
properties on the Wnt signaling pathway will provide
novel insights in support of a role for DICE1 protein in
prostate cancer progression and may potentially lead to
development of improved therapeutic approaches to
prostate cancer.
Methods
Cell Lines
Human immortalized normal prostate cells RWPE-1
(American Type Culture Collection; ATCC) were grown in
keratinocyte serum-free medium (Invitrogen, Carlsbad,
CA) supplemented with 25 μg/ml bovine pituitary extract
and 5 ng/ml epidermal growth factor. Human prostate
cancer cells LNCaP, DU145, PC3 and PC3-ml were grown
in RPMI 1640 medium supplemented with 10% fetal calf
serum (HyClone, Perbio Science, Erembodegem-Aalst,
Belgium) and 1% penicillin/streptomycin mix (Sigma,
Taufkirchen, Germany). Paired cancer/normal human
prostate cell lines, CPTX1532 and NPTX1532, were gener-
ated from patient undergoing radical prostatectomy and
established by immortalization after micro-dissection of
primary tumor cells and adjacent normal tissue respec-
tively [14]. NPTX1532 and CPTX1532 cell lines were cul-
tured in keratinocyte serum-free medium, 25 μg/ml
bovine pituitary extract, 5 ng/ml epidermal growth factor,
2 mM L-Glutamine, 10 mM HEPES, 50 ng/ml gentamicin
sulphate (all from Invitrogen, Carlsbad, CA), 5% heat
inactivated fetal bovin serum (BioWhitacker, Rockville,
MD), 2.5% penicillin/streptomycin mix (CellGro) and
0.5 μg/ml fungizone (CellGro). For transfection, prostate
cells (1 × 105) were seeded in 35 mm culture dish and
incubated overnight at 37°C. The cells were then trans-
fected for 4 hours with 4 μg pDICE1-EGFP expression
plasmid [13] or pEGFP control plasmid (Clontech) by
using the CLONfectin kit (Clontech) following the recom-
mended protocol. The transfection efficiencies were eval-
uated by counting the EGFP-positive cells under an
inverted fluorescent microscope (Axiovert 25CFL, Zeiss,
Göttingen, Germany), and reporting this number to the
total number of cells (regular light).
RNA isolation and Northern Blot analysis
BALB/c3T3 mouse cells were infected with retroviral par-
ticles containing either the full length DICE1 cDNA or no
insert. The retroviral packaging line Phoenix (provided by
Dr. Gary Nolan at Stanford University) was used for viral
transduction studies [23]. Cells were selected in 1 μg/ml
puromycin for 3 days. Total RNA was isolated following
the guanidinium isothiocyanate method of Chomczynski
and Sacchi [24]. Northern blot analysis was carried out
using 10 mg of total RNA in glyoxal agarose gels. Size frac-
tionated RNA was transferred to nylon filters electropho-
retically in 1× Tris Acetate EDTA buffer (TAE). Probes were
labeled by random priming and hybridization was carried
out using a solution of 7% SDS, 0.25 M Na3PO4, 5.6 mM
Na4P2PO7, 2 mM EDTA. Washing was carried out under
standard conditions.
Colony formation assay
After transfection, prostate cells were incubated over 2-3
weeks in the presence of G418 antibiotic (Sigma) to allow
colonies to develop. At the endpoint of the experiment,
the medium was removed, the colonies washed in PBS
and stained with 0.5% crystal violet (Sigma) in methanol.
Each colony formation assay was carried out in triplicate
and repeated at least three times. The working concentra-
tion of G418 (380 μg/ml for PC3 and 240 μg/ml for
DU145 cells) was defined as the lowest dose of antibiotic
that kills 100% of non-transfected cells in 5-7 days from
the start of G418 selection.
Western blot analysis
Cell extracts of EGFP and DICE1-EGFP transfected cells
were produced by RIPA lysis and separated by SDS-poly-
acrylamide gel electrophoresis (SDS-PAGE) according to
Harlow and Lane [25]. The gel was blotted on to a PVDF
transfer membrane (PVDF Polyscreen, NEN Life Science
Products, Boston, MA, USA) using a semi-dry blotting
device (Trans-blot SD, BioRad, München, Germany).
Immunodetection was carried out by using affinity-puri-
fied monoclonal anti-GFP antibody JL-8 (Living Colors,
Clontech, Palo Alto, U.S.A) and chemiluminescence as
described in [26].
Cell cycle analysis
For cell cycle analysis, prostate cells were trypsinized and
washed with ice-cold PBS. Then cells were fixed with 70%
ice-cold ethanol for 1 hour, followed by incubation in
freshly prepared nuclei staining buffer (200 μg/ml RNase
plus 20 μg/ml Propidium Iodide-PI in PBS) for 1 hour at
37°C. Cell cycle histograms were generated after analysis
of PI-stained cells by fluorescence-activated cell sorting
(FACS) with a Becton Dickinson FACVantage SE Cell
Sorter. For each sample, triplicates were performed and >1
× 104  events were recorded. Histograms generated by
FACS were analyzed by Cell Quest Software to determine
the percentage of cells in each phase (G1-S-G2/M). Statis-
tical evaluation of the data was done by paired Student's t
test using the SPSS 11.5 software for Windows. SE and P
values are shown where appropriate.
Reverse transcription polymerase chain reaction (RT-PCR)
Total RNA was isolated by using the RNeasy Mini kit (Qia-
gen GmBH, Hilden, Germany), following the manufac-
turer's recommendations. RNA (2.5 μg) of PC3 andCancer Cell International 2009, 9:28 http://www.cancerci.com/content/9/1/28
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DU145 cells were converted to cDNA by SuperScript III
Reverse Transcriptase, using a mixture of Oligo dT (0.25
μg) and Random Primer (0.5 μg; all from Invitrogen,
Carlsbad, CA, USA) in a volume of 11 μl RNase-free water.
Gene expression (Table 1) was quantified in triplicate
with the iCycler and MyIQ amplifiers (Bio-Rad) using a
SYBR-Green Supermix kit as recommended by the sup-
plier (Bio-Rad). The real-time PCR was performed with
primers and annealing temperatures described in table 2;
expression of each of the INTS6/DICE1 target genes was
quantified in three distinct batches of transfection.
RT2 Profiler PCR array system
The expression of 84 genes related to human Wnt signal-
ing pathway was analyzed in PC3 cells by quantitative
real-time PCR using RT2 Profiler PCR Array technology
(SABiosciences, Frederick, MD, USA). The provided Mas-
ter Mix, containing dNTP's, polymerase, MgCl2 and SYBR-
Green, and the cDNA were used as described by the man-
ufacturer. The RT-PCR reaction was performed in the iCy-
cler (Bio-Rad). For data analysis Ct values were used for
the gene of interest and the housekeeping gene glyceralde-
hyde-3-phosphate dehydrogenase (G3PDH). The relative
quantification of gene expression was determined using
the 2-ΔΔCT method as described by Livak and Schmittgen
[27].
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